Olmesartan/Hydrochlorothiazide STADA Arzneimittel AG 40 mg/12.5 mg film-coated tablets Իռլանդիա - անգլերեն - HPRA (Health Products Regulatory Authority)

olmesartan/hydrochlorothiazide stada arzneimittel ag 40 mg/12.5 mg film-coated tablets

stada arzneimittel ag - olmesartan medoxomil; hydrochlorothiazide - film-coated tablet - 40 mg/12.5 milligram(s) - angiotensin ii antagonists and diuretics; olmesartan medoxomil and diuretics

Olmesartan/Hydrochlorothiazide STADA Arzneimittel AG 40 mg/25 mg film-coated tablets Իռլանդիա - անգլերեն - HPRA (Health Products Regulatory Authority)

olmesartan/hydrochlorothiazide stada arzneimittel ag 40 mg/25 mg film-coated tablets

stada arzneimittel ag - olmesartan medoxomil; hydrochlorothiazide - film-coated tablet - 40 mg/25 milligram(s) - angiotensin ii antagonists and diuretics; olmesartan medoxomil and diuretics

Prucalopride STADA 1 mg film-coated tablets Իռլանդիա - անգլերեն - HPRA (Health Products Regulatory Authority)

prucalopride stada 1 mg film-coated tablets

stada arzneimittel ag - prucalopride - film-coated tablet - 1 milligram(s) - prucalopride

Prucalopride STADA 2 mg film-coated tablets Իռլանդիա - անգլերեն - HPRA (Health Products Regulatory Authority)

prucalopride stada 2 mg film-coated tablets

stada arzneimittel ag - prucalopride - film-coated tablet - 2 milligram(s) - prucalopride

Exemestan Stada 25mg Film-Coated Tablet Ֆիլիպիններ - անգլերեն - FDA (Food And Drug Administration)

exemestan stada 25mg film-coated tablet

stadapharm gmbh; importer: stada philippines, inc.; distributor: stada philippines, inc. - exemestane - film-coated tablet - 25mg

Cystadane Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

cystadane

pharmacy retailing (nz) ltd t/a healthcare logistics - betaine 180 g - powder for oral solution - 1 g - active: betaine 180 g - indicated as an adjunct in the treatment of homocystinuria. indicated to decrease elevated homocysteine blood levels in patients of all age groups with: 1. cystathionine beta-synthase (cbs deficiency) type homocystinuria, or 2. 5,10-methylenetetrahydrofolate reductase deficiency (mthfr deficiency), or 3. cobalamin cofactor metabolism defect (cbl defect) type of homocystinuria. indicated to increase methionine and s-adenosylmethionine blood levels in patients with 5,10-methylenetetrahydrofolate reductase deficiency (mthfr deficiency) and cobalamin cofactor metabolism defect (cbl defect) type of homocystinuria.

CYSTADANE betaine 1g/g oral powder bottle Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

cystadane betaine 1g/g oral powder bottle

recordati rare diseases australia pty ltd - betaine, quantity: 1 g/g - powder, oral - excipient ingredients: - as an adjunct in the treatment of homocystinuria.

cystadane- betaine, anhydrous powder, for solution Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

cystadane- betaine, anhydrous powder, for solution

jazz pharmaceuticals, inc. - betaine, anhydrous (unii: 3scv180c9w) (betaine, anhydrous - unii:3scv180c9w) - powder, for solution - 180 g in 1 g - cystadane (betaine anhydrous for oral solution) is indicated for the treatment of homocystinuria to decrease elevated homocysteine blood levels. included within the category of homocystinuria are deficiencies or defects in: - cystathionine beta-synthase (cbs), - 5,10-methylenetetrahydrofolate reductase (mthfr), - cobalamin cofactor metabolism (cbl ). patient response to cystadane can be monitored by homocysteine plasma levels (see dosage and administration). response usually occurs within a week and steady state within a month. cystadane has been administered concomitantly with vitamin b6 (pyridoxine), vitamin b12 (cobalamin), and folate.